Genetically engineered Tobacco mosaic virus as nanoparticle vaccines

References

• Harrison BD, Wilson TM. Milestones in the research on tobacco mosaic virus. Philos. Trans. R. Soc. Lond. B Biol. Sci.354(1383), 521–529 (1999).
   PubMed Web of Science ®Google Scholar
• Bos L. Beijerinck’s work on tobacco mosaic virus: historical context and legacy. Philos. Trans. R. Soc. Lond. B Biol. Sci.354(1383), 675–685 (1999).
   Google Scholar
• Kausche GA, Pfankuch E, Ruska H. Die Sichtbarmachung von pflanzlichem Viren im Ubermikroskop. Naturwissenschaften27, 292–299 (1939).
   Google Scholar
• Watson JD. The structure of Tobacco mosaic virus. I. X-ray evidence of a helical arrangement of sub-units around the longitudinal axis. Biochim. Biophys. Acta13(1), 10–19 (1954).
   PubMed Web of Science ®Google Scholar
• Van Regenmortel MH. The antigenicity of tobacco mosaic virus. Philos. Trans. R. Soc. Lond. B Biol. Sci.354(1383), 559–568 (1999).
   PubMed Web of Science ®Google Scholar
• Loor F. Comparative immunogenicities of Tobacco mosaic virus, protein subunits, and reaggregated protein subunits. Virology33(2), 215–220 (1967).
   Google Scholar
• Marbrook J, Matthews RE. The differential immunogenicity of plant viral protein and nucleoproteins. Virology28(2), 219–228 (1966).
   PubMedGoogle Scholar
• Butler PJ. Self-assembly of Tobacco mosaic virus: the role of an intermediate aggregate in generating both specificity and speed. Philos. Trans. R. Soc. Lond. B Biol. Sci.354(1383), 537–550 (1999).
   PubMed Web of Science ®Google Scholar
• Foss FM. Immunologic mechanisms of antitumor activity. Semin. Oncol.29(3 Suppl. 7), 5–11 (2002).
   PubMedGoogle Scholar
• Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat. Rev.1(3), 209–219 (2001).
   Google Scholar
• Vogel FR. Improving vaccine performance with adjuvants. Clin. Infect. Dis.30(Suppl. 3), S266–S270 (2000).
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res.20(4), 2665–2676 (2000).
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr. Mol. Med.7(2), 143–155 (2007).
   PubMed Web of Science ®Google Scholar
• Storni T, Kundig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev.57(3), 333–355 (2005).
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Fu N, Ossendorp F, Melief CJ. Ins and outs of dendritic cells. Int. Arch. Allergy Appl. Immunol.140(1), 53–72 (2006).
   Google Scholar
• Ardavin C, Amigorena S, Reis e Sousa C. Dendritic cells: immunobiology and cancer immunotherapy. Immunity20(1), 17–23 (2004).
   PubMedGoogle Scholar
• Basta S, Alatery A. The cross-priming pathway: a portrait of an intricate immune system. Scand. J. Immunol.65(4), 311–319 (2007).
   PubMedGoogle Scholar
• Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev.207, 166–183 (2005).
   PubMed Web of Science ®Google Scholar
• Ackerman AL, Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol.5(7), 678–684 (2004).
   PubMed Web of Science ®Google Scholar
• Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat. Immunol.5(10), 971–974 (2004).
   PubMed Web of Science ®Google Scholar
• Cresswell P, Ackerman AL, Giodini A, Peaper DR, Wearsch PA. Mechanisms of MHC class I-restricted antigen processing and cross-presentation. Immunol. Rev.207, 145–157 (2005).
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo.Immunobiology211(6–8), 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods (San Diego)40(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol.82(5), 506–516 (2004).
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol.173(5), 3148–3154 (2004).
   PubMed Web of Science ®Google Scholar
• Haynes JRC, von Seefried A, Lennick M, Garvin RT, Shen SH. Development of a genetically-engineered, candidate polio vaccine employing the self-assembling properties of the Tobacco mosaic virus coat protein. Bio/Technology4, 637–641 (1986).
   PubMedGoogle Scholar
• Palmer KE, Benko A, Doucette SA et al. Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes. Vaccine24(26), 5516–5525 (2006).
   PubMed Web of Science ®Google Scholar
• Smith ML, Lindbo JA, Dillard-Telm S et al. Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications. Virology348(2), 475–488 (2006).
   PubMed Web of Science ®Google Scholar
• Bendahmane M, Koo M, Karrer E, Beachy RN. Display of epitopes on the surface of tobacco mosaic virus: impact of charge and isoelectric point of the epitope on virus–host interactions. J. Mol. Biol.290(1), 9–20 (1999).
   PubMed Web of Science ®Google Scholar
• Koo M, Bendahmane M, Lettieri GA et al. Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope. Proc. Natl Acad. Sci. USA96(14), 7774–7779 (1999).
   PubMed Web of Science ®Google Scholar
• Werner S, Marillonnet S, Hause G, Klimyuk V, Gleba Y. Immunoabsorbent nanoparticles based on a Tobamovirus displaying protein A. Proc. Natl Acad. Sci. USA103(47), 17678–17683 (2006).
   PubMed Web of Science ®Google Scholar
• Turpen TH, Reinl SJ, Charoenvit Y, Hoffman SL, Fallarme V, Grill LK. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Bio/Technology13(1), 53–57 (1995).
   PubMed Web of Science ®Google Scholar
• Fitchen J, Beachy RN, Hein MB. Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response. Vaccine13(12), 1051–1057 (1995).
   PubMedGoogle Scholar
• Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev. Vaccines6(3), 381–390 (2007).
   PubMed Web of Science ®Google Scholar
• Pogue GP, Lindbo JA, McCulloch JA, Lawrence JE, Gross CS, Garger SJ. US 7,270,825. US Patent Office (Large Scale Biology Corporation) (2007).
   Google Scholar
• Jiang L, Li Q, Li M et al. A modified TMV-based vector facilitates the expression of longer foreign epitopes in tobacco. Vaccine24(2), 109–115 (2006).
   PubMedGoogle Scholar
• Wu L, Jiang L, Zhou Z et al. Expression of foot-and-mouth disease virus epitopes in tobacco by a tobacco mosaic virus-based vector. Vaccine21(27–30), 4390–4398 (2003).
   PubMedGoogle Scholar
• Lim AA, Tachibana S, Watanabe Y, Wong SM. Expression and purification of a neuropeptide nocistatin using two related plant viral vectors. Gene289(1–2), 69–79 (2002).
   Google Scholar
• Negrouk V, Eisner G, Midha S, Lee HI, Bascomb N, Gleba Y. Affinity purification of streptavidin using Tobacco mosaic virus particles as purification tags. Analyt. Biochem.333(2), 230–235 (2004).
   Google Scholar
• Miller RA, Presley AD, Francis MB. Self-assembling light-harvesting systems from synthetically modified tobacco mosaic virus coat proteins. J. Am. Chem. Soc.129(11), 3104–3109 (2007).
   PubMed Web of Science ®Google Scholar
• Li Q, Jiang L, Li M et al. Morphology and stability changes of recombinant TMV particles caused by a cysteine residue in the foreign peptide fused to the coat protein. J. Virol. Methods140(1–2), 212–217 (2007).
   Google Scholar
• Demir M, Stowell MHB. A chemoselective biomolecular template for assembling diverse nanotubular materials. Nanotechnology13, 541–544 (2002).
   Web of Science ®Google Scholar
• Smith ML, Corbo T, Bernales J et al. Assembly of trans-encapsidated recombinant viral vectors engineered from Tobacco mosaic virus and Semliki Forest virus and their evaluation as immunogens. Virology358(2), 321–333 (2007).
   Google Scholar
• McCormick AA, Corbo TA, Wykoff-Clary S et al. TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models. Vaccine24(40–41), 6414–6423 (2006).
   PubMed Web of Science ®Google Scholar
• McCormick AA, Corbo TA, Wykoff-Clary S, Palmer KE, Pogue GP. Chemical conjugate TMV-peptide bivalent fusion vaccines improve cellular immunity and tumor protection. Bioconjug. Chem.17(5), 1330–1338 (2006).
   PubMedGoogle Scholar
• Denis J, Majeau N, Acosta-Ramirez E et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. Virology363(1), 59–68 (2007).
   PubMed Web of Science ®Google Scholar
• Lacasse P, Denis J, Lapointe R, Leclerc D, Lamarre A. Novel plant virus-based vaccine induces protective CTL-mediated antiviral immunity through dendritic cell maturation. J. Virol.82(2), 785–794 (2007).
   Google Scholar
• Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat. Biotechnol.19(8), 760–764 (2001).
   PubMed Web of Science ®Google Scholar
• Pokorna D, Cerovska N, Smahel M et al. DNA vaccines based on chimeric potyvirus-like particles carrying HPV16 E7 peptide (aa 44–60). Oncology Reports14(4), 1045–1053 (2005).
   Google Scholar
• Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J. Endocrinol.193(3), 323–330 (2007).
   PubMed Web of Science ®Google Scholar
• O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev.7(5), 353–364 (2007).
   Google Scholar
• Hwang DJ, Roberts IM, Wilson TM. Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in Escherichia coli. Proc. Natl Acad. Sci. USA91(19), 9067–9071 (1994).
   Google Scholar
• Gallie DR, Sleat DE, Watts JW, Turner PC, Wilson TM. In vivo uncoating and efficient expression of foreign mRNAs packaged in TMV-like particles. Science236(4805), 1122–1124 (1987).
   Google Scholar
• Staczek J, Bendahmane M, Gilleland LB, Beachy RN, Gilleland HE Jr. Immunization with a chimeric tobacco mosaic virus containing an epitope of outer membrane protein F of Pseudomonas aeruginosa provides protection against challenge with P. aeruginosa. Vaccine18(21), 2266–2274 (2000).
   PubMed Web of Science ®Google Scholar